

Supplemental File 1: Search strategy

Database	# of refs	# of refs after de-duplication
Medline Ovid	867	193
embase.com	1365	1343
Web of science	1133	405
Google scholar	200	118
Total	3565	2059

12-06-2018

Medline Ovid

((oxidized low density lipoprotein.mp. AND (Antibodies/ OR Autoantibodies/ OR exp immunoglobulins/ OR exp Mast Cells/)) OR (((oxid* OR ox) ADJ6 (low-density-lipoprotein* OR ldl OR specific-epitope*) ADJ6 (antibod* OR anti OR autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*)) OR ((oxLDL* OR ose) ADJ3 (antibod* OR anti OR autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*))).ab,ti.) AND (exp arteriosclerosis/ OR (atherosclero* OR arteriosclero* OR athero-sclero* OR arterio-sclero* OR atherogenes* OR plaque* OR ((peripheral* OR coronar*) ADJ3 artery ADJ3 disease*) OR pad OR poad).ab,ti.) NOT (exp animals/ NOT humans/) AND english.la.

embase.com

('oxidized low density lipoprotein antibody'/exp OR (('oxidized low density lipoprotein'/de OR ('low density lipoprotein'/de AND (oxidation/de OR 'lipid oxidation'/de OR 'lipid peroxidation'/de))) AND ('immune response'/de OR antibody/de OR autoantibody/de OR 'antibody titer'/de OR 'antibody detection'/de OR 'immunoglobulin'/exp OR 'immunoglobulin antibody'/exp OR 'mast cell'/de)) OR (((oxid* OR ox) NEAR/6 (low-density-lipoprotein* OR ldl OR specific-epitope*) NEAR/6 (antibod* OR anti OR autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*)) OR ((oxLDL* OR ose) NEAR/3 (antibod* OR anti OR autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*))) :ab,ti) AND ('atherosclerosis'/exp OR 'arteriosclerosis'/exp OR 'peripheral occlusive artery disease'/exp OR 'coronary artery disease'/exp OR (atherosclero* OR arteriosclero* OR athero-sclero* OR arterio-sclero* OR atherogenes* OR plaque* OR ((peripheral* OR coronar*) NEAR/3 artery NEAR/3 disease*) OR pad OR poad):ab,ti) NOT ([animals]/lim NOT [humans]/lim) AND [english]/lim

Web of science

TS=((((oxid* OR ox) NEAR/5 (low-density-lipoprotein* OR ldl OR specific-epitope*) NEAR/5 (antibod* OR anti OR autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*)) OR ((oxLDL* OR ose) NEAR/2 (antibod* OR anti OR

autoantibod* OR Immune-respon* OR immunoglobulin* OR Igg* OR ige* OR igm* OR iga* OR mast-cell*)) AND ((atherosclero* OR arteriosclero* OR athero-sclero* OR arterio-sclero* OR atherogenes* OR plaque* OR ((peripheral* OR coronar*) NEAR/2 artery NEAR/2 disease*) OR pad OR poad))) AND LA=(english)

Google scholar

"oxidized low-density-lipoprotein"|"ox ldl"|oxldl anti|antibodies|antibody atherosclerosis|arteriosclerosis|atherogenesis|plaque|"peripheral|coronary artery diseases|disease"

Supplemental Table 1. Quality control

	First author	Year	Selection				Comparability*	Outcome/Exposure			Total
cohort studies			<i>Representativeness of the exposed cohort</i>	<i>Selection of the non-exposed cohort</i>	<i>Ascertainment of exposure</i>	<i>Demonstration that outcome of interest was not present at start of study</i>	<i>Comparability of cohorts on the basis of the design or analysis</i>	<i>Assessment of outcome</i>	<i>Was follow-up long enough for outcomes to occur</i>	<i>adequacy of follow-up of cohorts</i>	number of stars awarded/ maximum number of stars
	Björkbacka	2016	*	NA	*		**	*	*	*	7/8
	Maiolino†	2013	*	NA	*	*	**	*	*		7/8
	Meeuwse	2017	*	NA	*		**	*	*	*	7/8
	Prasad	2017	*	NA	*		**		*	*	6/8
	Tsimikas†	2007	*	NA	*	*			*		4/8
	Tsimikas	2012	*	NA	*		**	*	*	*	7/8
	Wilson	2006	*	NA	*	*	**	*	*	*	8/8
Case-control studies			<i>Case definition</i>	<i>Representativeness of the cases</i>	<i>Selection of controls</i>	<i>definition of controls</i>	<i>Comparability of cases and controls on the basis of the design or analysis</i>	<i>Ascertainment of exposure</i>	<i>same method of ascertainment for cases and controls</i>	<i>non-response rate</i>	number of stars awarded/ maximum number of stars
	Khamis	2016		*	*	*	**	*	NA	NA	6/7
	Ravendi	2011		*	*	*	**	*	NA	NA	6/7
	Van den Berg	2018		*	*	*	**	*	NA	NA	6/7
Cross-sectional studies			<i>Representativeness of the sample</i>	<i>Sample size</i>	<i>Non-respondents</i>	<i>Ascertainment of the exposure (risk factor)</i>	<i>Comparability of subjects in different outcome groups</i>	<i>Assessment of the outcome</i>	<i>Statistical test</i>		number of stars awarded/ maximum number of stars
	Bilgen	2005	*		NA	**					3/9
	Che	2011	*		NA	**			*		4/9
	Chen	2011	*		NA	**	*				4/9
	Garrido-Sanchez	2009	*		NA						1/9
	Gruzdeva	2014	*		NA	**					3/9
	Maiolino†	2012	*		NA	**					3/9
	Moohebbati	2014	*		NA	**					3/9
	Rossi	2003	*	*	NA	**	*	**			7/9
	Soto	2009	*		NA	**		*			4/9
	Tsimikas†	2007	*		NA	**	*		*		5/9

** Comparability can be rated with two stars*

† Article applied both cohort design and cross-sectional design